The role of gut microbiota in digestive system cancers: mechanisms and potential therapeutic targets

The rising prevalence of digestive system cancersincluding colorectal, stomach, esophageal, and pancreatic cancersposes significant global health challenges, exacerbated by the elusive early-stage symptoms that lead to late-stage diagnoses with poor prognoses. Emerging evidence suggests a substantial role of gut microbiota in the pathogenesis of these malignancies. This paper reviews the complex interactions between the gut microbiota and the host, particularly focusing on dysbiosis and its contributions to carcinogenesis through mechanisms like chronic inflammation, immune response alterations, and carcinogenic metabolite production. Epidemiological data highlight the incidence and mortality rates associated with these cancers, emphasizing the influence of lifestyle, environmental factors, and genetics, with a newfound focus on microbial compositions. The gut microbiota's role extends from influencing metabolic profiles to impacting regulatory T-cell functions and inflammatory pathways, which are pivotal in tumor progression. Specific bacteria such as Clostridium nucleatum and Helicobacter pylori are scrutinized for their direct associations with colorectal and stomach cancers, respectively. Furthermore, the review discusses potential therapeutic interventions targeting microbial dysbiosis, such as dietary modifications, probiotics, and microbiota-targeted therapies, which could revolutionize treatment paradigms. This comprehensive analysis aims to underscore the gut microbiota as a critical factor in digestive system oncology, providing insights into future research directions and novel therapeutic strategies